

REMARKS

The title has been amended to more accurately reflect the subject matter of the amended claims. Claims 1-12 have been canceled, and new claims 13-28 have been added. Support for the amendments to the claims and for the added claims is found throughout the specification and the claims as filed, as for example at page 4, line 30 through page 5, line 33; at page 13, line 28 through page 14, line 32; at page 21, lines 28-36; at page 22, lines 20-29; and at page 30, line 32 through page 33, line 20. No new matter has been added.

Correction of Inventorship

The Examiner is requested to note that as a result of the amendment of the claims to be drawn to polypeptides related to SEQ ID NO:25, the inventorship of the application is to be changed in accordance with the petition under 37 CFR 1.48(b) submitted herewith.

Information Disclosure Statement

An Information Disclosure Statement and Form PTO-1449 for the present application are being submitted herewith.

If a telephone interview would be helpful in advancing the prosecution of this application, Applicants' attorney invites the Examiner to contact her at the number provided below.

Respectfully submitted,


Suzanne A. Sprunger, Ph.D.
Attorney for Applicants
Registration No. 41,323
Telephone (206) 265-7071

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119